For example, the SELECT trial clearly demonstrated that semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease ( ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)
Insulin resistance and type 2 diabetes mellitus are associated with ectopic fat deposition not only in the liver and heart, as is well recognized, but also in the pancreas
This matters as much for casual visitors as for strategy-minded regulars who plan sessions around budget, volatility, and risk tolerance
The healthcare sector is experiencing a significant shift with the introduction of Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) for the purchase of semaglutide, a medication renowned for its weight loss efficacy
Many patients report this is when they truly start believing the medication is working
Bourguet W, Germain P, Gronemeyer H